Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits tumor growth
|
| gptkbp:class |
antineoplastic agent
immunomodulator |
| gptkbp:clinical_trial |
Phase 3
newly diagnosed multiple myeloma relapsed multiple myeloma |
| gptkbp:effective_date |
2015-07-24
|
| gptkbp:formulation |
lyophilized powder for solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sylvant
|
| gptkbp:ingredients |
gptkb:dexamethasone
C22 H28 N2 O5 S |
| gptkbp:is_atype_of |
L01 XX
|
| gptkbp:is_used_for |
treatment of multiple myeloma
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Celgene_Corporation
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea thrombocytopenia increased risk of infection |
| gptkbp:type_of |
123456-78-9
|
| gptkbp:bfsParent |
gptkb:siltuximab
|
| gptkbp:bfsLayer |
4
|